{"url_path":"/sec/nams/8-k/2026-06-03/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1936258/0001193125-26-254615-index.html","accession_number":"0001193125-26-254615","cik":"0001936258","ticker":"NAMS","issuer_name":"NewAmsterdam Pharma Co N.V.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1936258/0001193125-26-254615-index.html","primary_entity_key":"0001936258","primary_entity_name":"NewAmsterdam Pharma Co N.V."},"word_count":83,"has_tables":true,"body_markdown":"## Item 9.01 Financial Statements and Exhibits.\n\n(d)\n\nExhibits.\n\nExhibit No.\n\n \n\nDescription\n\n \n\n \n\n10.1\n\n \n\n[NewAmsterdam Pharma Company N.V. 2026 Employee Stock Purchase Plan.](nams-ex10_1.htm)\n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\nNewAmsterdam Pharma Company N.V.\n\n \n\n \n\n \n\n \n\nDate:\n\nJune 3, 2026\n\nBy:\n\n/s/ Mike Marino\n\n \n\n \n\nName:\n\nMike Marino\n\n \n\n \n\nTitle:\n\nChief Legal Officer"}